Get the Stockscreener App
6.69
2.21%
0.13
After Hours:
6.70
0.010
+0.15%
Entrada Therapeutics Inc stock is traded at $6.69, with a volume of 466.91K.
It is up +2.21% in the last 24 hours and down -46.91% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$6.56
Open:
$6.61
24h Volume:
466.91K
Relative Volume:
1.34
Market Cap:
$259.71M
Revenue:
$25.42M
Net Income/Loss:
$-143.75M
P/E Ratio:
-1.9275
EPS:
-3.4709
Net Cash Flow:
$-129.55M
1W Performance:
+18.67%
1M Performance:
-46.91%
6M Performance:
-33.48%
1Y Performance:
-10.60%
1-Day Range:
$6.325
$6.84
1-Week Range:
$5.70
$6.84
52-Week Range:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.69 | 254.66M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
View All
Entrada Therapeutics Inc Stock (TRDA) Latest News
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDA - Finviz
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com Australia
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
User - The Chronicle-Journal
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679 - Minichart
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress - TipRanks
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors - Stock Titan
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Scott Coop
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(TRDA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Entrada Therapeutics faces investigation after drug trial results disappoint, stock plunges 57%. - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price Today & Analysis - Gotrade
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
HC Wainwright Has Positive Estimate for TRDA Q2 Earnings - MarketBeat
TradingKey - TradingKey
Investors in Entrada Therapeutics urged to join probe after stock drops on clinical trial results - Pluang
Entrada Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MSN Money - MSN
Transcript : Entrada Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile - Barchart.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock SelloffHere's Why - Sahm
Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co. - Moomoo
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Entrada Therapeutics(TRDA.US) to Hold Rating - Moomoo
Entrada’s stock drops as DMD drug’s efficacy falls short - Yahoo Finance
Entrada Therapeutics Declines on Duchenne Muscular Dystrophy Study Data -- Update - Moomoo
Entrada’s ENTR-601-44 Shows Efficacy, But Dystrophin Raises Questions - Citeline News & Insights
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entrada sinks on mixed DMD data with ENTR-601-44 - BioWorld News
Entrada Therapeutics Announces Positive Topline Results from Coho - The National Law Review
Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ) - Seeking Alpha
Entrada shares sink after Duchenne drug falls short of expectations - WHTC
Entrada Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sethuraman Natarajan | President, Research & Develop. |
May 04 '26 |
Sale |
15.39 |
25,907 |
398,810 |
216,317 |
| Dowden Nathan J | President & COO |
May 04 '26 |
Option Exercise |
1.74 |
15,000 |
26,100 |
213,588 |
| Dowden Nathan J | President & COO |
May 04 '26 |
Sale |
15.33 |
15,000 |
229,953 |
198,588 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):